Lymphoma, Large-Cell, Anaplastic
"Lymphoma, Large-Cell, Anaplastic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A systemic, large-cell, non-Hodgkin, malignant lymphoma characterized by cells with pleomorphic appearance and expressing the CD30 ANTIGEN. These so-called "hallmark" cells have lobulated and indented nuclei. This lymphoma is often mistaken for metastatic carcinoma and MALIGNANT HISTIOCYTOSIS.
Descriptor ID |
D017728
|
MeSH Number(s) |
C04.557.386.480.750.399 C15.604.515.569.480.750.600 C20.683.515.761.480.750.399
|
Concept/Terms |
Lymphoma, Large-Cell, Anaplastic- Lymphoma, Large-Cell, Anaplastic
- CD30-Positive Anaplastic Large-Cell Lymphoma
- CD30 Positive Anaplastic Large Cell Lymphoma
- Ki-1 Lymphoma
- Ki 1 Lymphoma
- Ki-1 Lymphomas
- Lymphoma, Ki-1
- Lymphomas, Ki-1
- Systemic Anaplastic Large-Cell Lymphoma
- Systemic Anaplastic Large Cell Lymphoma
- Anaplastic Large-Cell Lymphoma
- Anaplastic Large Cell Lymphoma
- Anaplastic Large-Cell Lymphomas
- Large-Cell Lymphoma, Anaplastic
- Large-Cell Lymphomas, Anaplastic
- Lymphoma, Anaplastic Large-Cell
- Lymphomas, Anaplastic Large-Cell
- CD30+ Anaplastic Large-Cell Lymphoma
- CD30+ Anaplastic Large Cell Lymphoma
- Lymphoma, Large-Cell, Ki-1
|
Below are MeSH descriptors whose meaning is more general than "Lymphoma, Large-Cell, Anaplastic".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Lymphoma [C04.557.386]
- Lymphoma, Non-Hodgkin [C04.557.386.480]
- Lymphoma, T-Cell [C04.557.386.480.750]
- Lymphoma, Large-Cell, Anaplastic [C04.557.386.480.750.399]
- Hemic and Lymphatic Diseases [C15]
- Lymphatic Diseases [C15.604]
- Lymphoproliferative Disorders [C15.604.515]
- Lymphoma [C15.604.515.569]
- Lymphoma, Non-Hodgkin [C15.604.515.569.480]
- Lymphoma, T-Cell [C15.604.515.569.480.750]
- Lymphoma, Large-Cell, Anaplastic [C15.604.515.569.480.750.600]
- Immune System Diseases [C20]
- Immunoproliferative Disorders [C20.683]
- Lymphoproliferative Disorders [C20.683.515]
- Lymphoma [C20.683.515.761]
- Lymphoma, Non-Hodgkin [C20.683.515.761.480]
- Lymphoma, T-Cell [C20.683.515.761.480.750]
- Lymphoma, Large-Cell, Anaplastic [C20.683.515.761.480.750.399]
Below are MeSH descriptors whose meaning is more specific than "Lymphoma, Large-Cell, Anaplastic".
This graph shows the total number of publications written about "Lymphoma, Large-Cell, Anaplastic" by people in this website by year, and whether "Lymphoma, Large-Cell, Anaplastic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2007 | 1 | 0 | 1 |
2009 | 1 | 0 | 1 |
2012 | 1 | 0 | 1 |
2014 | 0 | 1 | 1 |
2017 | 1 | 0 | 1 |
2018 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lymphoma, Large-Cell, Anaplastic" by people in Profiles.
-
Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trümper L. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019 01 19; 393(10168):229-240.
-
Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Fenton K, Huebner D, Pinelli JM, Kennedy DA, Shustov A. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017 12 21; 130(25):2709-2717.
-
Herrera AF, Crosby-Thompson A, Friedberg JW, Abel GA, Czuczman MS, Gordon LI, Kaminski MS, Millenson MM, Nademanee AP, Niland JC, Rodig SJ, Rodriguez MA, Zelenetz AD, LaCasce AS. Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network. Cancer. 2014 Jul 01; 120(13):1993-9.
-
Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Shustov A. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012 Jun 20; 30(18):2190-6.
-
Sanka RK, Eagle RC, Wojno TH, Neufeld KR, Grossniklaus HE. Spectrum of CD30+ lymphoid proliferations in the eyelid lymphomatoid papulosis, cutaneous anaplastic large cell lymphoma, and anaplastic large cell lymphoma. Ophthalmology. 2010 Feb; 117(2):343-51.
-
Sevilla DW, Choi JK, Gong JZ. Mediastinal adenopathy, lung infiltrates, and hemophagocytosis: unusual manifestation of pediatric anaplastic large cell lymphoma: report of two cases. Am J Clin Pathol. 2007 Mar; 127(3):458-64.